AT&T Completes Sale-Leaseback
As part of its legacy network transformation, AT&T Inc. (NYSE: T) completed a structured sale-leaseback of underutilized central office facilities with private real estate development firm Reign Capital.The transaction, which closed on Jan. 8, includes the asset transfer of 74 properties, located across the country, encompassing over 13 million square feet of space. The transaction generates more than $850 million in upfront cash proceeds for AT&T through a unique deal structure that enables future profit sharing from redevelopment opportunities."The uniquely structured deal unlocks value in otherwise stranded commercial real estate space," said Michael Ford, head of global real estate, AT&T. "It's a creative solution providing both upfront and long-term value through a revenue sharing model that fits with our broader company and transformation initiatives."Central offices were originally built to house and connect large, bulky, and energy-intensive equipment for outdated copper networks. As customers move from copper to fiber and wireless, a smaller, more efficient equipment footprint is managing the network. This technology evolution not only reduces power consumption, benefitting the environment, but also lowers operating costs and frees up valuable real estate for other uses.Friday, the communications giant began trading up 19 cents to $22.72.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


